Complete atrioventricular block during galantamine therapy;Totaal atrioventriculair blok tijdens behandeling met galantamine

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 10, 2006, Pages 563-566

  Leentjens, A F G ^a   Kragten, J A ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE;

ALZHEIMER DISEASE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; COMPLETE HEART BLOCK; DEMENTIA; ELECTROCARDIOGRAM; HUMAN; RATING SCALE; REVIEW;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; ELECTROCARDIOGRAPHY; GALANTAMINE; HEART BLOCK; HUMANS; MALE; PACEMAKER, ARTIFICIAL;

EID: 33644938438     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Duijn CM van. Epidemiologie. In: Jonker C, Verhey FRJ, Slaets JPJ, redacteuren. Alzheimer en andere vormen van dementie. Houten: Bohn Stafleu van Loghum; 2001. p. 9-18.
2. Werkgroep 'Richtlijn diagnostiek en medicamenteuze behandeling van dementie'. Richtlijn diagnostiek en medicamenteuze behandeling van dementie. Alphen aan den Rijn: Van Zuiden Communications; 2005.
3. College voor zorgverzekeringen (CVZ). Farmacotherapeutisch kompas 2005. Diemen: CVZ; 2004.
4. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
5. Blessed G, Tomlinson BE, Roth M. The association of quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
6. Beek C van der, Toenders WGM. De ziekte van Alzheimer, diagnostiek en medicamenteuze behandeling; richtlijnen voor de praktijk. Amstelveen: College voor zorgverzekeringen; 2000.
7. Maltz MS, Kirschenbaum HL. Galantamine: a new acetylcholine-sterase inhibitor for the treatment of Alzheimer's disease. Drug Forecast. 2002;27:135-8.
8. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol. 2002;42:558-68.
9. Bordier P, Garrigue S, Barold SS, Bressolles N, Lanusse S, Clementy J. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace. 2003;5:429-31.
10. Cozanitis DA, Nuuttila K, Karhunen P, Baraka A. Changes in cardiac rhythm with galanthamine hydrobromide. Anaesthesist. 1973;22: 457-9.
11. n Calvo-Romero JM, Ramos-Salado JL. Bradicardia sinusal sintomatica asociada a donepecilo. Rev Neurol. 1999;28:1070-2.
12. Yano H, Fukuhara Y, Wada K, Kowa H, Nakashima K. [A case of cholinergic adverse effects induced by donepezil overdose: a follow-up of clinical course and plasma concentration of donepezil.] Rinsho Shinkeigaku. 2003;43:482-6.
13. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother. 1999;33:812-5.
14. Allal C, Lazartigues E, Tran MA, Brefel-Courbon C, Gharib C, Montastruc JL, et al. Central cardiovascular effects of tacrine in the concious dog: a role for catecholamines and vasopressin release. Eur J Pharmacol. 1998;348:191-8.
15. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res. 1993;27:453-8.
16. Walsh E, Dourish J. Prolonged QT interval with rivastigmine. Br J Psychiatry. 2002;180:466.